Fine-tuning CARs for best performance

Alastair Hotblack; Karin Straathof

doi:10.1016/j.ccell.2021.12.010

Fine-tuning CARs for best performance

Cancer Cell. 2022 Jan 10;40(1):11-13. doi: 10.1016/j.ccell.2021.12.010.

Authors

Alastair Hotblack¹, Karin Straathof²

Affiliations

¹ University College London (UCL) Great Ormond Street Institute of Child Health, London, UK; UCL Cancer Institute, London, UK.
² University College London (UCL) Great Ormond Street Institute of Child Health, London, UK; UCL Cancer Institute, London, UK. Electronic address: k.straathof@ucl.ac.uk.

PMID: 35016025
DOI: 10.1016/j.ccell.2021.12.010

Abstract

Chimeric antigen receptors (CARs) allow redirection of T cells against any surface antigen. However, CARs require optimization to achieve activity against low-density antigens. Heitzeneder et al. perform an iterative adjustment of CAR components to reach a design for targeting cerebroglycan (GPC2) that shows potent pre-clinical activity in neuroblastoma models.

Publication types

Comment

MeSH terms

Glypicans
Humans
Neuroblastoma*
Receptors, Chimeric Antigen* / genetics
T-Lymphocytes

Substances

Glypicans
Receptors, Chimeric Antigen

Grants and funding

20769/CRUK_/Cancer Research UK/United Kingdom